← Leaderboards
Zhongyun Dong
University Of Cincinnati
$3,681,500
Attributed
$3,681,500
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $323.7K · FY2005–23$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,681,500 · 4
By mechanism
R01$2,890,582 · 2
R21$790,918 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Cincinnati
Same institution · by research overlap
- Nicholas Brown$69,689
- Camille Sullivan$75,646
- Andrew Paluch$118,158
Others in their field
Top investigators on “Cell Growth”
- David Heimbrook · Leidos Biomedical Research, Inc.$112,725,505
- Garret A Fitzgerald · University Of Pennsylvania$101,611,429
- Barton F Haynes · Duke University$92,250,940
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$80,656,368
- Jennifer A Pietenpol · Vanderbilt University$70,361,058
- Max S. Wicha · University Of Michigan At Ann Arbor$68,808,891
Research focus
Cell GrowthGrowthTumor GrowthProteinsCellsMalignant Neoplasm Of ProstateTumorStructureTherapeutic EffectLncapGenesReceptorOverexpressionPathway InteractionsMediatingStanoloneReceptor ExpressionIn VitroReceptor SignalingDown-RegulationAndrogen ReceptorLigand Binding DomainComplexGene Expression
Grant awards (14)
Proliferating cell nuclear antigen in regulation of androgen receptor signalings in castration-resistant prostate cancer cells$185,552
R21 · FY2023 · CA · contact PI
Proliferating cell nuclear antigen in regulation of androgen receptor signalings in castration-resistant prostate cancer cells$227,205
R21 · FY2022 · CA · contact PI
Preclinical safety and efficacy assessment of a novel PCNA inhibitor for prostate cancer therapy$169,307
R21 · FY2019 · CA · contact PI
Preclinical safety and efficacy assessment of a novel PCNA inhibitor for prostate cancer therapy$208,854
R21 · FY2018 · CA · contact PI
A Novel Synthetic Androgen Receptor Antagonist$313,989
R01 · FY2012 · CA · contact PI
A Novel Synthetic Androgen Receptor Antagonist$313,989
R01 · FY2011 · CA · contact PI
A Novel Synthetic Androgen Receptor Antagonist$323,700
R01 · FY2010 · CA · contact PI
A Novel Synthetic Androgen Receptor Antagonist$323,700
R01 · FY2009 · CA · contact PI
A Novel Synthetic Androgen Receptor Antagonist$323,700
R01 · FY2008 · CA · contact PI
TGF-beta 1-regulated IL-8 expression in prostate cancer$243,853
R01 · FY2007 · CA · contact PI
TGF-beta 1-regulated IL-8 expression in prostate cancer$251,136
R01 · FY2006 · CA · contact PI
TGF-beta 1-regulated IL-8 expression in prostate cancer$257,180
R01 · FY2005 · CA
TGF-beta 1-regulated IL-8 expression in prostate cancer$270,555
R01 · FY2004 · CA
TGF-beta 1-regulated IL-8 expression in prostate cancer$268,780
R01 · FY2003 · CA